“We are thrilled to partner with Dr. Zambelli-Weiner and her team of scientific and medical experts at TTI to provide a powerful AI solution to the healthcare industry,” said BullFrog AI’s Founder and CEO, Vin Singh.
BALTIMORE (PRWEB)
May 21, 2020
BullFrog AI, Inc., a precision pharmaceutical company built around a powerful artificial intelligence (AI) platform, proudly announces its newest partnership with TTi Health Research & Economics. TTi Health Research & Economics will acquire drug development, medtech and other healthcare-focused projects with a focus on clinical data analytics with their team of scientific and medical experts.
“We are thrilled to partner with Dr. Zambelli-Weiner and her team of scientific and medical experts at TTI to provide a powerful AI solution to the healthcare industry,” said BullFrog AI’s Founder and CEO, Vin Singh. “This commercial relationship is expected to be an important revenue generator for our company and positions us well for the launch of our extended seed round next month.”
“I’m excited about our partnership with BullFrog AI and how it enhances our toolkit to address complex healthcare challenges in a post-pandemic marketplace where reducing the cost of product development and evidence generation will be more important than ever,” said TTi’s Founder and CEO, Dr. April Zambelli-Weiner. “This partnership will benefit our clients by allowing us to harness the power of real world data to identify actionable information to support commercialization, from identifying subgroups of patients who can benefit most from a therapeutic drug or device to predicting patients at highest risk of adverse outcomes to identifying the most promising intermediate or surrogate endpoints for clinical studies to demonstrate the clinical utility of new products.”
For more information on BullFrog AI, visit http://www.bullfrogai.com. For more information on TTi Health Research & Economics, visit /ttiresearch.com.
About BullFrog AI
BullFrog AI is an innovator in artificial intelligence. Its proprietary bfLEAPTM analytics engine is the only tool of its kind, designed to analyze massive, complex, multi-factorial clinical data sets. BullFrog AI’s technology is poised to revolutionize drug development, enabling researchers and clinicians to match therapies to patients, streamlining clinical trials, reducing development costs and accelerating R&D cycle time to drug approval and commercial launch. BullFrog AI has an exceptional team of life science industry leaders, AI technologists, scientists, physicians and advisors, all determined to make BullFrog AI become the undisputed leader in precision medicine.
About TTi Health Research & Economics
Headquartered in Maryland, TTi serves a diverse clientele, focusing on medical device companies, and including all stakeholders in the health space who have a vested interest in improving patient outcomes, population health, and access to care. TTi is known for our ability to bring practical, actionable solutions to address complex healthcare challenges. Our team of veteran health economists, epidemiologists, data scientists, statisticians and market access experts offer our clients creative, cost-effective solutions to develop, prove and communicate the value of therapeutics, policies and programs to the marketplace and to support widespread adoption and implementation to advance the triple aim of healthcare.
For more information regarding BullFrog AI, contact:
Vin Singh
Founder and CEO
Vin@Bullfrogai.com
301-367-2055
http://www.BullFrogAI.com
Baltimore, Maryland
For Media Inquiries, please contact:
Liz Thibodeau
Thibodeau Media Group
Liz@thibmedia.com
Share article on social media or email: